PARIS, April 3, 2009 (AFP) - A new antibiotic has passed a key phase in a test of drugs aimed at shortening the time to cure tuberculosis, offering a potential boon in the fight against TB, according to a study reported in The Lancet on Saturday.
The standard treatment for TB is a course of drugs that takes up to six months -- a time that is so long that many patients, believing they are cured because they no longer feel symptoms of the disease, abandon the therapy.
As a result, they may not have been completely cleared of the germ that causes TB, and this enables the microbe to mutate into a drug-resistant form or be passed on to other individuals.
In the quest for a fast-track cure, doctors tested a new antibiotic called moxifloxacin in conjunction with the standard medications among a group of 170 patients in Brazil.
Among those who had moxifloxacin added to their regime, 80 percent tested negative for the TB bacterium in their sputum by the end of the eighth week. In the non-moxifloxacin group, the success rate was only 63 percent.
The trial was a so-called Phase II study in the long and demanding three-phase process of testing new drugs for safety and effectiveness.
In 2007, 9.27 million people contracted TB, an increase of about 30,000 over the previous year mainly in line with population growth, according to the World Health Organisation.
They included some 1.4 million people who were coinfected with HIV/AIDS. Half a million people are believed to have strains of TB that are resistant to frontline drugs.
090403
AF090401
Copyright ©AFP 2009. All Rights Reserved. AFP articles contained on the AEGiS web site may not be reproduced, distributed, transmitted, displayed, published or broadcast without AFP's prior written permission. You may make one copy of each article for your personal, non-commercial use only; more copies would require AFP's prior written permission obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP photos or materials. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP stories, photos or graphics. http://www.afp.com/
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.